

August 10, 2010



Quick-Med's New NIMBUS(R) Advanced Active Wound Dressing Improves Healing

Novel Wound Dressing Developed for U.S. Army Under Small Business Innovation Research Grant

GAINESVILLE, Fla., Aug. 10, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today the development of a new prototype wound dressing, NIMBUS^(R) Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a \$900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.

Active wound care products combine advanced wound care features such as an antimicrobial barrier with properties that actively promote wound healing and tissue growth. Though still in its infancy, the active wound care segment already accounts for more than \$1.5 billion of the \$14 billion global wound care market.

Quick-Med scientists have demonstrated significant improvements in wound healing using the NIMBUS Advanced Active dressing in *in vitro* experiments with chemically injured human tissue. As a next phase of Quick-Med's SBIR research, animal studies using NIMBUS Advanced Active wound dressings have been conducted at Battelle Memorial Institute. When the results of these *in vivo* studies are reported later this year, Quick-Med expects to see enhanced, complication-free improvements in wound healing based on histological evidence.

"Preliminary findings of the *in vivo* animal studies demonstrate that NIMBUS Advanced Active can combine actives and control their release to enhance wound healing. These

agents can perform additional functions without diminishing the dressing's antimicrobial performance," said Dr. Jerry Olderman, Quick-Med's Vice President of R&D. "NIMBUS Advanced Active is the ultimate multi-functional dressing, with applicability for acute and chronic wounds. Its multiple agents will aid wound healing of many types of acute and chronic injuries. We look forward to receiving the final report on the animal study confirming the results of its healing capabilities."

NIMBUS Advanced Active is a superabsorbent dressing that provides controlled release of a protease inhibitor, antioxidants and epidermal growth factor to stimulate skin regeneration. Derived from Quick-Med's NIMBUS technology, the NIMBUS Advanced Active dressing has broad applicability to all classes of wounds including difficult to treat thermal and chemical burns, and provides a moist wound healing environment with non-leaching antimicrobial protection.

"NIMBUS Advanced Active is a unique wound dressing. There's nothing like it on the market today," said J. Ladd Greeno, Quick-Med's CEO. "We believe that NIMBUS Advanced Active, when commercialized, can significantly aid in the healing process for a wide range of difficult to heal chronic wounds."

Quick-Med will continue to pursue the features of this very unique and flexible active wound dressing as it completes the final report phase of its research work under the U.S. Army SBIR grant. The Company will also seek qualified partners to commercialize its new NIMBUS Advanced Active wound dressing technology.

About NIMBUS^(R)

Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received de Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters. NIMBUS Advanced Active is a prototype dressing that has not received FDA clearance.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.

(C) 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS^(R) is a registered trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are

made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

Contact:

Quick-Med Technologies
J. Ladd Greeno, CEO
(888) 835.2211 Ext 102
jgreeno@quickmedtech.com
The Ruth Group
Media
Eric Reiss
(646) 536-7032
ereiss@theruthgroup.com
Investors
Ashleigh Barreto
(646) 536-7028
abarreto@theruthgroup.com